Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07IQR
|
||||
| Former ID |
DNC006104
|
||||
| Drug Name |
3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527996] | ||
| Formula |
C20H18N4O3
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=CC(=C3)C(=O)N
|
||||
| InChI |
1S/C20H18N4O3/c21-18(25)15-8-4-9-16(12-15)23-20(26)24-19-17(10-5-11-22-19)27-13-14-6-2-1-3-7-14/h1-12H,13H2,(H2,21,25)(H2,22,23,24,26)
|
||||
| InChIKey |
RLBJUMUHKDTSCO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Peptidyl-prolyl cis-trans isomerase A | Target Info | Inhibitor | [527996] | |
| Reactome | Platelet degranulation | ||||
| Uncoating of the HIV Virion | |||||
| Budding and maturation of HIV virion | |||||
| Integration of provirus | |||||
| Early Phase of HIV Life Cycle | |||||
| Minus-strand DNA synthesis | |||||
| Plus-strand DNA synthesis | |||||
| Binding and entry of HIV virion | |||||
| Assembly Of The HIV Virion | |||||
| APOBEC3G mediated resistance to HIV-1 infection | |||||
| Basigin interactions | |||||
| References | |||||